Vivus land $30M for Phase III work

Vivus has garnered a $30 million funding collaboration with Deerfield Management to advance work on the company's ED drug avanafil. Using $20 million from a Royalty and Funding Agreement and $10 million from the sale of Vivus common stock, Deerfield will finance a Phase III study of the drug. "The collaboration with Deerfield allows us to move avanafil into the phase 3 clinical trials on a timely basis. The funding collaboration provides us with financial flexibility and allows us to leverage the MUSE franchise for the benefit of avanafil development," stated Vivus' CEO Leland Wilson

- here's the press release for more

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.